ATE556719T1 - Impfstoff gegen menschliche influenza, der vier peptide aus influenza enthält - Google Patents

Impfstoff gegen menschliche influenza, der vier peptide aus influenza enthält

Info

Publication number
ATE556719T1
ATE556719T1 AT10003160T AT10003160T ATE556719T1 AT E556719 T1 ATE556719 T1 AT E556719T1 AT 10003160 T AT10003160 T AT 10003160T AT 10003160 T AT10003160 T AT 10003160T AT E556719 T1 ATE556719 T1 AT E556719T1
Authority
AT
Austria
Prior art keywords
influenza
epitopes
human
peptides
epitope
Prior art date
Application number
AT10003160T
Other languages
German (de)
English (en)
Inventor
Ruth Arnon
Tamar Ben-Yedidia
Raphael Levi
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE556719T1 publication Critical patent/ATE556719T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT10003160T 1998-11-30 1999-11-28 Impfstoff gegen menschliche influenza, der vier peptide aus influenza enthält ATE556719T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL12733198A IL127331A0 (en) 1998-11-30 1998-11-30 Peptide-based vaccine for influenza

Publications (1)

Publication Number Publication Date
ATE556719T1 true ATE556719T1 (de) 2012-05-15

Family

ID=11072200

Family Applications (1)

Application Number Title Priority Date Filing Date
AT10003160T ATE556719T1 (de) 1998-11-30 1999-11-28 Impfstoff gegen menschliche influenza, der vier peptide aus influenza enthält

Country Status (15)

Country Link
US (3) US6740325B1 (https=)
EP (2) EP1135159A2 (https=)
JP (1) JP2002531415A (https=)
KR (1) KR100703571B1 (https=)
AT (1) ATE556719T1 (https=)
AU (1) AU766883B2 (https=)
BR (1) BR9915811A (https=)
CA (1) CA2352454C (https=)
DK (1) DK2204187T3 (https=)
ES (1) ES2389611T3 (https=)
HK (1) HK1040620A1 (https=)
IL (3) IL127331A0 (https=)
NZ (1) NZ511918A (https=)
PT (1) PT2204187E (https=)
WO (1) WO2000032228A2 (https=)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
AU2002223398A1 (en) * 2000-08-10 2002-04-08 Tsinghua University A vaccine for influenza virus and its preparation
FI20031536A0 (fi) * 2003-10-20 2003-10-20 Biotie Therapies Oyj Korkean affiniteetin ligandit influenssavirukselle ja menetelmät niiden valmistamiseen
ES2372633T3 (es) 2003-11-04 2012-01-25 The Administrators Of The Tulane Educational Fund Procedimiento de evitar condensación de virus: células inhibiendo la función de la región de iniciación de condensación en los virus arn que tienen proteínas de envoltura fusogénicas de membrana de clase i.
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
US8420102B2 (en) * 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
US20060177468A1 (en) * 2005-01-05 2006-08-10 Philadelphia Health and Education Corporation (d/b/a Drexel University College of Medicine Delivery vehicles, bioactive substances and viral vaccines
EP2374474A1 (en) 2005-01-19 2011-10-12 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
FI20060200A0 (fi) * 2005-04-20 2006-02-27 Glykos Finland Oy Menetelmä ihmisen influenssaviruksen sialihahappositoumisspesifisyyden analysoimiseksi
MX2007015105A (es) * 2005-06-01 2008-03-18 Variation Biotechnologies Inc Formulacion de vacuna de influenza a base de peptido.
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
CA2627105A1 (en) * 2005-10-26 2007-05-03 Protelix, Inc. Influenza combinatorial antigen vaccine
EP1951862B1 (en) * 2005-11-07 2013-07-24 MicroVAX, LLC Cd40 ligand fusion protein vaccine
PT1968632E (pt) * 2005-12-06 2012-07-16 Yeda Res & Dev Vacina da gripe melhorada
PL2478916T3 (pl) * 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US20080208486A1 (en) * 2006-03-23 2008-08-28 Jari Natunen Integrated System, Device and Use Thereof
US8222204B2 (en) 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
US20110129438A1 (en) * 2006-06-28 2011-06-02 James Robert Swartz Immunogenic protein constructs
FI20060946A0 (fi) * 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
US20090060889A1 (en) * 2007-03-12 2009-03-05 Von Hofe Eric Ii-RNAi involved Ii suppression in cancer immunotherapy
EA017887B1 (ru) * 2007-08-02 2013-03-29 Байондвакс Фармасьютикалз Лтд. Полимерные мультиэпитопные вакцины против гриппа
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
EP2278997B1 (en) 2008-04-21 2016-08-10 Nanobio Corporation Nanoemulsion influenza vaccine
BRPI0911604A2 (pt) * 2008-04-25 2015-12-15 Inst Systems Biology vacinas de polipeptídeo de flagelina
EP2286223B1 (en) * 2008-05-02 2016-07-06 University Of Rochester Arrayed detector system for measurement of influenza immune response
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
JP5854559B2 (ja) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
BR112013018074A2 (pt) 2011-01-13 2020-12-01 Variation Biotechnologies, Inc. métodos para a preparação de vesículas e formulações produzidas a partir dessas
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
EP2729169A1 (en) 2011-07-06 2014-05-14 Nanobio Corporation Human respiratory syncytial virus vaccine
JP6205360B2 (ja) 2011-08-22 2017-09-27 ナノバイオ コーポレーション 単純ヘルペスウイルスのナノエマルジョンワクチン
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CN103961306A (zh) 2013-02-05 2014-08-06 日东电工株式会社 经皮给予用疫苗组合物
IN2014CH00396A (https=) 2013-02-05 2015-04-03 Nitto Denko Corp
EP2762152A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
CA2840997A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
KR20140100419A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
CN103961697A (zh) 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
KR102050931B1 (ko) 2013-02-05 2019-12-02 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 테이프제
RU2687026C2 (ru) 2013-02-05 2019-05-06 Нитто Денко Корпорейшн Вакцинная композиция против злокачественной опухоли на основе пептида wt1 для мукозального введения
CN103961700A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
EP2762157A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
RU2531235C2 (ru) * 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
CN103901202B (zh) * 2014-04-04 2015-08-12 中国人民解放军成都军区疾病预防控制中心 基于共有表位甲型流感病毒抗体通用型竞争性elisa检测方法
JP6577795B2 (ja) 2014-09-03 2019-09-18 日東電工株式会社 ビスホスホネート剤を含む細胞性免疫用ワクチン医薬組成物
CN106687127A (zh) 2014-09-03 2017-05-17 日东电工株式会社 含有双膦酸盐剂的体液免疫用疫苗药物组合物
EP3332809A4 (en) 2015-08-06 2019-04-10 Nitto Denko Corporation COMPOSITION FOR IMMUNITY INDUCTION PROMOTION AND PHARMACEUTICAL VACCINE COMPOSITION
KR20190129032A (ko) 2016-12-28 2019-11-19 인벡스, 인크. 인플루엔자 백신

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
IL101639A0 (en) 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
WO1997044667A2 (fr) * 1996-05-21 1997-11-27 Institut Pasteur Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules t antigene-specifiques et pour stimuler des cellules t
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza

Also Published As

Publication number Publication date
IL143367A0 (en) 2002-04-21
IL127331A0 (en) 1999-09-22
WO2000032228A3 (en) 2000-10-05
EP2204187A1 (en) 2010-07-07
EP1135159A2 (en) 2001-09-26
US20070122424A1 (en) 2007-05-31
US7514086B2 (en) 2009-04-07
WO2000032228A2 (en) 2000-06-08
ES2389611T3 (es) 2012-10-29
KR20010089512A (ko) 2001-10-06
NZ511918A (en) 2003-08-29
EP2204187B1 (en) 2012-05-09
AU1406600A (en) 2000-06-19
BR9915811A (pt) 2001-08-21
JP2002531415A (ja) 2002-09-24
PT2204187E (pt) 2012-08-10
IL143367A (en) 2006-09-05
HK1145448A1 (en) 2011-04-21
CA2352454C (en) 2013-02-05
KR100703571B1 (ko) 2007-04-05
US20050002954A1 (en) 2005-01-06
US6740325B1 (en) 2004-05-25
CA2352454A1 (en) 2000-06-08
DK2204187T3 (da) 2012-08-20
AU766883B2 (en) 2003-10-23
US7192595B2 (en) 2007-03-20
HK1040620A1 (zh) 2002-06-21

Similar Documents

Publication Publication Date Title
ATE556719T1 (de) Impfstoff gegen menschliche influenza, der vier peptide aus influenza enthält
JP2002531415A5 (https=)
Schild et al. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide.
AR008765A1 (es) Un peptido o un derivado, analogo o variante, funcional del mismo, un peptido recombinante o sintetico del mismo, una secuencia nucleotidica y vectorque la contiene, una celula huesped transformada, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un compuesto del
ES2619332T3 (es) Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
AR038568A1 (es) Anticuerpos anti-a beta y su uso
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
ES2060603T3 (es) El uso de la proteina vp6 nucleocapsida de rotavirus en composiciones de vacunas.
ES2531142T3 (es) Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
GR1001550B (el) Αλατα βασικών πεπτιδίων με πολυεστέρες που έχουν ακραία ομάδα καρβοξύ.
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
BR9106220A (pt) Antigenos sinteticos para a deterccao de anticorpos para o virus da hepatite c.
CY1105763T1 (el) Αναλογα γλυκοπρωτεϊνικων ορμονων δισουλφιδικης σταυρωτης συνδεσης, η παρασκευη και η χρηση τους
Stryhn et al. Shared fine specificity between T-cell receptors and an antibody recognizing a peptide/major histocompatibility class I complex.
ATE175119T1 (de) Vakzine gegen immunodefizienz-virus der katze (kiv)
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
TW200505943A (en) Polypeptide
DE69110891D1 (de) Peptide und analoge und mischungen davon zum nachweis der gegen die viren htlv-1 und htlv-ii gerichteten antikörper.
RU94040393A (ru) Синтетические пептиды для вакцины против краснухи
Beauverger et al. Serotype-specific and canine distemper virus cross-reactive H-2Kk-restricted cytotoxic T lymphocyte epitopes in the measles virus nucleoprotein
BR0107175A (pt) Peptìdeos miméticos para epitopo de apolipoproteìna b-100, concatemero e seus peptìdeos modificados, e composição de vacina compreendendo os mesmos
ATE208421T1 (de) Stimulierung der immunantwort durch virales protein
Cole et al. T cell recognition of the immunodominant Sendai virus NP324-332/Kb epitope is focused on the center of the peptide